Previously treated metastatic colorectal cancer
Conditions
Interventions
None listed
Sponsors
West Japan Oncology Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically or cytologically diagnosed adenocarcinoma of the colon or rectum (excluding the appendix and anal canal) 2) Tumor is clinically determined to be unresectable for a radical cure 3) Age of 20 or older 4) ECOG PS of 0-2 5) Measurable or non-measurable lesion according to RECIST, version 1.1. 6) FTD/TPI plus BEV was started before 31st October 2020 without history of chemotherapy including fluoropyrimidine, oxaliplatin, or irinotecan. 7) History of chemotherapy prior to FTD/TPI plus BEV 8) Not identified as fit by investigator 9) Retained organ function
Exclusion criteria
Exclusion criteria: 1) History of chemotherapy including regorafenib, FTD/TPI, or investigational drug prior to FTD/TPI plus BEV
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival Time to treatment failure Objective response rate Disease control rate Adverse event Proportion of subsequent therapy Efficacies according to previous therapy and treatment line Reason for being vulnerable | — |
Countries
Japan
Contacts
Public ContactShinichiro Nakamura
West Japan Oncology Group WJOG datacenter
Outcome results
None listed